{"id":"W4408161023","doi":"10.1038/s41591-025-03566-1","title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Pembrolizumab; Oncology; Endometrial cancer; Medicine; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Overall survival; Gynecology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003380079,0.001166561,0.002376917,0.0002851635,0.0003350664,0.0008313681,0.0007144735,0.001124976,0.003735617],"category_scores_gemma":[0.003361486,0.0004086075,0.00300935,0.0004153902,0.0007477775,0.001124263,0.0004662368,0.002600624,0.0004855451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008621443,"about_ca_system_score_gemma":0.001168181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001009793,"about_ca_topic_score_gemma":0.002989814,"domain_scores_codex":[0.9985475,0.001098467,0.00005154985,0.0001339917,0.00005718387,0.0001113116],"domain_scores_gemma":[0.9985725,0.0006155816,0.0003440909,0.0001464625,0.00005968106,0.0002616722],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9813712,0.001057406,0.00130325,0.0003826911,0.002295209,0.00002852585,0.00003030639,0.0004733999,0.00100957,0.00009310647,0.0006114675,0.01134377],"study_design_scores_gemma":[0.9401243,0.04804569,0.006570089,0.00007572163,0.002878523,0.00005151008,0.00003674599,0.000684867,0.0002450297,0.0003533124,0.0009179964,0.000016185],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854594,0.008094127,0.0006809857,0.0009708118,0.0002848604,0.001317618,0.00125492,0.00006579635,0.001871544],"genre_scores_gemma":[0.9905922,0.002275848,0.001288369,0.0008917463,0.0002035713,0.001886971,0.001323152,0.00002300599,0.001515227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003735617,"threshold_uncertainty_score":0.01787573,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04493321513930112,"score_gpt":0.4229879946054951,"score_spread":0.3780547794661939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}